Leo Fong, MD
Vascular Surgery · Clovis, CANPI 1215047659
Payments from drug & device makers
Across 636 payments — averaging $780.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$315K
- Medline Industries LP$118K
- Organogenesis Inc.$26K
- Medtronic$23K
- Penumbra, Inc.$7K
- Abbott$2K
- plus $4K from 28 others
Across 2 payments — averaging $6562.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Integra Lifesciences Corporation$13K
What the payments were for
- Speaking & faculty fees$25,51353%
- Travel & lodging$8,20517%
- Food & beverage$14,68430%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 137 | $314,699 |
| Medline Industries LP | 10 | $118,161 |
| Organogenesis Inc. | 211 | $26,103 |
| Medtronic(2 entities) | 36 | $23,328 |
| Penumbra, Inc. | 19 | $7,456 |
| Abbott | 110 | $2,469 |
| Bard Peripheral Vascular, Inc. | 30 | $952 |
| Mimedx Group, Inc. | 11 | $624 |
| Boston Scientific | 6 | $310 |
| Shockwave Medical, Inc | 8 | $276 |
| E.r. Squibb & Sons, L.L.C. | 13 | $244 |
| Johnson & Johnson | 7 | $194 |
| Veryan Medical Incorporated | 1 | $190 |
| Philips North America LLC | 2 | $147 |
| Integra Lifesciences Corporation | 1 | $141 |
| Venclose Inc. | 1 | $138 |
| Cardiovascular Systems Inc. | 8 | $116 |
| W. L. Gore & Associates, Inc. | 2 | $115 |
| Koya Medical, Inc. | 1 | $104 |
| Cook Medical LLC | 3 | $91 |
| BD | 3 | $90 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $67 |
| Urgo Medical North America, LLC | 3 | $65 |
| Elutia, Inc. | 1 | $63 |
| Tactile Systems Technology Inc | 2 | $53 |
| Hartmann USA, Inc. | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Inari Medical, Inc. | 1 | $25 |
| Abiomed | 1 | $24 |
| Bolton Medical Inc | 1 | $21 |
| Cordis US CORP. | 1 | $20 |
| KCI USA, Inc. | 1 | $18 |
| Osiris Therapeutics Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PURAPLY WOUND MATRIX$21,867
- VenaSeal$6,166
- Indigo System$4,964
- Affinity$2,510
- Apligraf$2,305
- NOVACHOR$2,145
- NuShield$2,145
- RUBY Coil$2,138
- Diamondback Peripheral$453
- INTEGRA$422
- CYGNUS DUAL$355
- Dayspring$311
- Penumbra System$285
- BioMimics 3D Vascular Stent System$190
- Perclose ProGlide suture mediated closure system$182
- INTEGRA DERMAL REGENERATION TEMPLATE$141
- PRIMATRIX$141
- EVRSF$138
- Venclose Maven Catheter$137
- (6582) Visions 035$134
How this compares
$496,383 in reported general payments places this provider in the 95th percentile of 519 vascular surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 37 | $58,245 |
| XareltoRivaroxaban | 33 | $33,249 |
| ClopidogrelClopidogrel Bisulfate | 83 | $814 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $587 |
| Gabapentin | 44 | $296 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 82 | $295 |
| Levofloxacin | 21 | $292 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $181 |
| SsdSilver Sulfadiazine | 16 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $314,699 | $58,24537 claims |
| Johnson & JohnsonXarelto | $194 | $33,24933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 519 vascular surgery providers in California.
Other vascular surgery in Clovis
- Venita ChandraPalo Alto$947K
- Leigh Ann ObanionFresno$932K
- Sukgu HanLos Angeles$765K
- Mahmoud Malasla Jolla$508K
- Son DuongFountain Valley$503K
- Jason LeePalo Alto$403K
- Bernardo Curi MendesLos Angeles$376K
- Trevor DerderianRancho Mirage$359K
- Karthikeshwar KasirajanPalo Alto$349K
- Johnathon RolloLos Angeles$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.